| dc.contributor.author | Ranganath, Sudhir H. | |
| dc.contributor.author | Levy, Oren | |
| dc.contributor.author | Inamdar, Maneesha S. | |
| dc.contributor.author | Karp, Jeffrey Michael | |
| dc.contributor.author | Ranganath, Sudhir H. | |
| dc.date.accessioned | 2014-11-14T17:10:12Z | |
| dc.date.available | 2014-11-14T17:10:12Z | |
| dc.date.issued | 2012-03 | |
| dc.identifier.issn | 19345909 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/91575 | |
| dc.description.abstract | The broad repertoire of secreted trophic and immunomodulatory cytokines produced by mesenchymal stem cells (MSCs), generally referred to as the MSC secretome, has considerable potential for the treatment of cardiovascular disease. However, harnessing this MSC secretome for meaningful therapeutic outcomes is challenging due to the limited control of cytokine production following their transplantation. This review outlines the current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart disease. We discuss ongoing investigative directions aimed at improving cellular activity and characterizing the secretome and its regulation in greater detail. Finally, we provide insights on and perspectives for future development of the MSC secretome as a therapeutic tool. | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (NIH Grant HL097172) | en_US |
| dc.description.sponsorship | National Institutes of Health (U.S.) (NIH Grant HL095722) | en_US |
| dc.description.sponsorship | Sanofi Aventis (Firm) (JNCASR grant) | en_US |
| dc.description.sponsorship | Indo-US Science and Technology Forum ((IUSSTF) grant) | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Elsevier B.V. | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1016/j.stem.2012.02.005 | en_US |
| dc.rights | Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. | en_US |
| dc.source | Elsevier | en_US |
| dc.title | Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Ranganath, Sudhir H., Oren Levy, Maneesha S. Inamdar, and Jeffrey M. Karp. “Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease.” Cell Stem Cell 10, no. 3 (March 2012): 244–258. © 2012 Elsevier B.V. | en_US |
| dc.contributor.department | Harvard University--MIT Division of Health Sciences and Technology | en_US |
| dc.contributor.mitauthor | Ranganath, Sudhir H. | en_US |
| dc.contributor.mitauthor | Levy, Oren | en_US |
| dc.contributor.mitauthor | Karp, Jeffrey Michael | en_US |
| dc.relation.journal | Cell Stem Cell | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Ranganath, Sudhir H.; Levy, Oren; Inamdar, Maneesha S.; Karp, Jeffrey M. | en_US |
| mit.license | PUBLISHER_POLICY | en_US |
| mit.metadata.status | Complete | |
